Welcome to the third and final part of Dr. Stanislaw Burzynski's TTAC Live '19 presentation! If you need to catch up on Part 1 [http://bit.ly/dr-burzynski-pt1] or Part 2 [http://bit.ly/right-to-try-act-part2], please do so then come back here to find out about the success rates from Dr. Burzynski's precision cancer treatment process.

If you would prefer to read along, please visit our website for this clip's transcript: bit.ly/right-to-try-pt3.

Dr. Burzynski's precision cancer treatment success stems from the combination of immunotherapy, genomic testing, and intravenous or oral antineoplastons. Keep watching to learn more about this complex topic and how the Right to Try Act is helping connect more cancer patients to successful post-clinical trial treatments like this.